UK markets close in 7 hours 45 minutes

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.3877-0.0324 (-7.71%)
As of 04:16PM BST. Market open.

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797
https://aimimmuno.com

Sector(s)
Industry
Full-time employees26

Key executives

NameTitlePayExercisedYear born
Mr. Thomas K. Equels Esq., J.D., M.S.Executive Vice Chairman, CEO & President953.19kN/A1953
Mr. Robert Dickey IV, M.B.A.Chief Financial Officer64.48kN/A1956
Mr. Peter W. Rodino III, Esq., J.D.COO, Executive Director of Governmental Relations, General Counsel & Secretary484.94kN/A1951
Ann Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorN/AN/AN/A
Dr. Carol A. SmithChief Manufacturing Officer & Deputy Chief Scientific Officer170.77kN/A1951
Dr. Christopher McAleer Ph.D.Scientific OfficerN/AN/AN/A
Dr. Ralph Christopher Cavalli Ph.D.Vice President of QC & Manufacturing234.79kN/A1958
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Corporate governance

AIM ImmunoTech Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.